Throughout 2018, Lupus News Today brought you coverage of important discoveries, potential disease markers, treatment developments, and clinical trials related to lupus. As we look forward to reporting more news to patients, family members, and caregivers in 2019, here are the Top 10 most-read articles of 2018. No. 10 —…
The addition of low-dose voclosporin to standard therapy led to significantly greater remission but a higher incidence of adverse events in systemic lupus erythematosus (SLE) patients with active lupus nephritis, according to a Phase 2 clinical trial. Findings from the trial were published in the study, “…
The levels of galectin-3 binding protein (G3BP) in urine could be used as a biomarker of renal disease activity for systemic lupus erythematosus (SLE) patients with lupus nephritis, according to a study. The study, “Urinary Galectin-3 Binding Protein As a Novel Biomarker of Renal Disease Activity…
A low dose of the immunosuppressant leflunomide is as safe and effective as the standard of care cyclophosphamide for induction treatment of patients with lupus nephritis, according to a Phase 2/3 trial in China. Trial findings were published in the study, “Leflunomide versus cyclophosphamide in the induction…
The investigational compound evobrutinib acts on the immune system by promoting anti-inflammatory behavior of macrophages — immune cells that engulf and digest pathogens — and the death of pro-inflammatory ones, a study reports. This suggests benefits in systemic lupus erythematosus (SLE) and rheumatoid arthritis besides the suppression of B-cells.
Systemic lupus erythematosus (SLE) patients using hydroxychloroquine have a markedly lower risk of a type of abnormal heart rhythm called atrial fibrillation than those not being treated with the therapy, according to a retrospective study. The research, “Association of Hydroxychloroquine Use and Incident Atrial Fibrillation in…
Using Benlysta (belimumab) as a maintenance therapy after Rituxan (rituximab) leads to similar kidney function in patients with lupus nephritis compared with Rituxan alone, according to a Phase 2 clinical trial. The research, “Phase 2 Trial of Induction Therapy with Anti-CD20 (Rituximab) Followed By Maintenance Therapy with Anti-BAFF…
One year of treatment with ustekinumab led to sustained reductions in disease activity in systemic lupus erythematosus (SLE) patients, according to a Phase 2 trial. These benefits were also observed in patients who switched from placebo to Janssen‘s therapy at week 24. Trial findings were presented in the study, “…
Corticosteroids and hydroxychloroquine are the most common medications used by patients with systemic lupus erythematosus (SLE) or lupus nephritis (LN), according to a real-world study, which also found very limited use of biologics. The study, “Real World Medication Use in Incident Systemic Lupus Erythematosus and…
The activity of systemic lupus erythematosus (SLE) is persistently high in a large proportion of patients, despite high rates of steroids and immunosuppressants use, according to a five-year study. The findings indicate gaps in effectiveness of current SLE treatments, new research has found. The research, “Persistent Disease…